Efficacy of Collagen Matrix for Peri-implant Soft Tissue Phenotype Modification

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age21+
SponsorMohammed Bin Rashid University of Medicine and Health Sciences

About this trial

A stable band of keratinized mucosa (KM) around dental implants is thought to minimize tissue recession and provide resistance against mechanical, chemical, and microbial challenges, thereby preserving peri-implant tissue health. Soft tissue augmentation is often employed to enhance the soft tissue phenotype in such cases. While autogenous grafts such as free gingival grafts (FGG) remain the gold standard, xenogeneic collagen matrices (XCM) have emerged as promising alternatives, offering reduced patient morbidity and surgical time. This randomized controlled clinical trial aims to compare the clinical efficacy and patient-reported outcome measures (PROMs) of XCM versus FGG for soft tissue phenotype modification when performed during healing abutment connection around dental implants, with evaluations at both short-term (6 months) and long-term (1 and 2 years) intervals.

Thirty participants will be recruited at Dubai Health Dental Hospital and randomly assigned to receive either XCM (test) or FGG (control) augmentation. Clinical assessments will be conducted at baseline (T0), 2 weeks (T2w), and at 1 (T1), 3 (T3), 6 (T6), 12 (T12), and 24 (T24) months post-surgery.

The primary outcome is the change in KM width, measured from the mucosal margin to the mucogingival junction. Secondary outcomes include KM thickness, supracrestal tissue height, and soft tissue dimensional changes, assessed using intraoral scans (Trios 5) and superimposed STL files. Additional measurements include peri-implant soft tissue level and phenotype.

PROMs will be recorded in the first postoperative week and at the 3-year mark using a visual analog scale (VAS). Clinical indices such as plaque index, bleeding index, and probing depth will be evaluated at 6 months, 1 year, and 2 years. Marginal bone level changes and implant survival rates will also be tracked throughout the study period.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Aged 21 or over.

Insufficient KM width (< 2 mm) at the buccal aspect of implants at time of healing abutment placement, either for single anterior or posterior implants.

Controlled oral hygiene (full-mouth plaque and bleeding scores ≤ 25% at baseline).

Good compliance and commitment to attend follow-up review appointments.

Disqualifiers

Smoking

Untreated localized or generalized periodontal diseases

Uncontrolled systemic diseases

Long term use of non-steroidal anti-inflammatory medications

Trial design

Design model

Parallel

Treatments tested in this trial

  • Soft tissue substitute for peri-implant phenotype modification

    Procedure/Surgery

    XCM (Mucograft©, Geistlich Pharma® AG, Wolhusen, Switzerland) placed at the time of healing abutment connection and its impact on peri-implant soft tissue phenotype modification when

  • Control Group - Free gingival graft for soft tissue augmentation

    Procedure/Surgery

    Free gingival graft around implants placed at the time of healing abutment connection and its impact on peri-implant soft tissue phenotype modification

Treatment groups

30 Participants
are divided into 2 treatment groups
Group A: Test group - MucograftExperimental treatment 1 intervention
Group B: Control Group - Free gingival graftActive comparator 1 intervention

Trial outcomes

Primary outcomes

1

Changes in Keratinized Mucosa width

Changes in KM width - as measured from the free mucosal margin to the mucogingival junction at the mid-buccal aspect of the implant abutment or crown with a UNC-15 probe; at the follow-up time point relative to the baseline at T0

Time frame
6 months

Secondary outcomes

1

Changes in KM thickness and supracrestal tissue height

calculating percentage of KM width (shrinkage), KM thickness and supracrestal tissue attachment reduction at the follow-up time point relative to the baseline at T0.

Time frame
6 months

Other outcomes

1

Patient reported outcome measures (PROMs)

PROMs will be assessed during the first week post-surgery and at the 3-year follow-up using a visual analog scale (VAS) with scores ranging from 0 to 100. First week post-surgery, patients will be asked to complete a questionnaire on days 1 and 7 to evaluate post-surgical morbidity, including pain, swelling, and bleeding as well as to record the dosage of analgesics. At the 6 months follow-up, the patients will be asked to assess their comfort, satisfaction with the color and shape of the grafted area, willingness for retreatment, and overall satisfaction, all using the VAS.

Time frame
6 months

Sponsors and contacts

Click on the lead sponsor to view all of their trials.